Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer
- 20 March 2017
- journal article
- research article
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 37 (5) , 649-654
Abstract
The aim of this study was to evaluate the efficacy and toxicity profile of oral etoposide (50 mg/day, days 1–14, every 3 weeks) in recurrent platinum-resistant epithelial ovarian cancer (EOC). 52 recurrent platinum-resistant EOC patients followed up in four centres between April 2000 and December 2013 were analysed retrospectively. There was response in a total of 21 patients [partial response (PR) and stable disease (SD)], 12 of them used etoposide in second and third, and 9 of them used it in fourth- to fifth-lines of treatment. The overall response rate was 19.2% and clinical benefit rate was 40.4% [PR (19.2%), SD (21.2%)]. Median overall survival (OS) and progression-free survival (PFS) was 9.95 months (95%CI, 0.2–19.7 months) and 3.2 months (95%CI 2.6–3.8 months), respectively. Grade III–IV haematologic and non-haematologic adverse events were observed in 7 (13.4%) patients. We consider that oral etoposide (50 mg/day, days 1–14, every 3 weeks) is an effective treatment with a manageable adverse effect profile in recurrent platinum-resistant EOC patients.Keywords
This publication has 25 references indexed in Scilit:
- Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503)Gynecologic Oncology, 2015
- Second-Line Treatment with Intravenous Gemcitabine and Oral Etoposide in Platinum-Resistant Advanced Ovarian Cancer Patients: Results of a Phase II StudyOncology, 2011
- Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroupJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Ovarian neoplasia: epidemiology and etiology2009
- Daily low-dose oral etoposide for recurrent epithelial ovarian cancer after platinum-based therapyJournal of Obstetrics and Gynaecology, 2004
- Phase II study of prolonged oral etoposide in refractory ovarian cancerInternational Journal of Gynecological Cancer, 1995
- Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapyAnnals of Oncology, 1994
- Oral etoposide is active against platinum-resistant epithelial ovarian cancer.Journal of Clinical Oncology, 1994
- Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancerJournal of Cancer Research and Clinical Oncology, 1992